

Influenza B Victoria lineage egg-derived¹ candidate vaccine viruses for the development and production of vaccines for use in the 2024 southern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise specified, all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. [National or Regional control authorities approve the composition and formulation of vaccines used in each country](#)²

29 September 2023 (last updated 25 January 2024)

Candidate vaccine viruses antigenically like B/Austria/1359417/2021 (egg derived) - Accession number (GISAID): EPI_ISL_1519459

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
B/Austria/1359417/2021	Wild type virus			WHO CCs MHRA, UK
	BVR-26	Classical	Seqirus	MHRA, UK NIID, Japan VIDRL, Australia
	BX-107A	Classical	NYMC	CDC, USA MHRA, UK NYMC, USA
B/Michigan/01/2021	Wild type virus			CDC, USA MHRA, UK NIID, Japan
B/Singapore/WUH4618/2021	Wild type virus			WHO CCs MHRA, UK
B/Guangdong-Zhenjiang/1516/2021	Wild type virus			WHO CCs
	CNIC-2107A	Classical	CCDC, China	WHO CCs MHRA, UK
B/Zhejiang-Nanhu/1854/2021	Wild type virus			WHO CCs
	BX-117	Classical	NYMC	MHRA, UK NYMC, USA
B/Zhejiang-Xiacheng/11085/2021	Wild type virus			WHO CCs MHRA, UK
	BX-115	Classical	NYMC	NYMC, USA
B/Shaanxi-Baota/1278/2022	Wild type virus			WHO CCs MHRA, UK
	BX-121	Classical	NYMC	NYMC, USA
	BX-121A	Classical		

Institutes contact details for candidate vaccine virus orders/information:

CCDC: whocc-china@cnic.org.cn
CDC: pdx1@cdc.gov (Subject: CVV request)
FCI: whocc@crick.ac.uk
MHRA: standards@nibsc.org or enquiries@nibsc.org
NIID: flu-vaccine@nih.go.jp
NYMC: doris_bucher@nymc.edu

¹ For cell-derived candidate vaccine viruses and reference reagents please see <https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses>

² <https://www.who.int/initiatives/who-listed-authority-reg-authorities>

VIDRL: whoflu@influenzacentre.org
 WHO CCs: http://www.who.int/influenza/gisrs_laboratory/collaborating_centres/list/en/

Reference antigens (freeze-dried)

Parent virus	Starting materials		Ref Ag Lot number	Unitage (µg HA/ml)	Available from
	Candidate vaccine virus	Egg or cell			
B/Austria/1359417/2021	BVR-26	Egg	2023BVA	49	NIID, Japan
			2023BVB	59	
			21/316	52	MHRA, UK
			2021/139B	90	TGA, Australia
B/Michigan/01/2021	Wild type virus	Egg	B(v)-Ag-2117	77	CBER/FDA, USA
			21/330	74	MHRA, UK

Sheep antisera

Purified HA from		Order	Available from
Parent virus	Egg or Cell	Lot number	
B/Austria/1359417/2021-like	Egg	B(v)-Ab-2202	CBER/FDA, USA
		B(v)-Ab-2308	
		22/228*	MHRA, UK
		2022BV-1*	NIID, Japan
		AS446-1	TGA, Australia
		AS452	

**New reagents shown in blue*

The above-listed potency testing reagents have been developed with support from manufacturers and calibrated by the WHO Essential Regulatory Laboratories (ERLs) of the Global Influenza Surveillance and Response System (GISRS).

ERLs contact details for reagents orders/information:

CBER: CBERShippingRequests@fda.hhs.gov
 MHRA: standards@nibsc.org or enquiries@nibsc.org
 NIID: flu-vaccine@nih.go.jp
 TGA: influenza.reagents@health.gov.au

The list of all WHO Collaborating Centres (CCs) and Essential Regulatory Laboratories (ERLs) for influenza can be found on the WHO web site at <https://www.who.int/initiatives/global-influenza-surveillance-and-response-system/who-collaboration-center-erl?CxitPEOtTWx0xUd5TJdODSXcnyJqzYd7FZeivpn7xcl=>

For other candidate vaccine viruses and potency testing reagents, please go to <https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses>

For general enquiries, please contact gisrs-whohq@who.int